MAP3K4

Across TCGA pan-cancer cohorts, MAP3K4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAP3K4 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MAP3K4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP3K4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where MAP3K4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.509	0.840	.006	37	view →
CCRCC	DFS	Quartile	All	0.931	0.699	.017	8	view →
UCEC	OS	Tertile	All	0.846	1.000	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAP3K4–PDAC (DFS)

Open the PDAC breakdown →